“…The patient population consisted of patients with autoimmune or cholestatic liver disease (19 studies), [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] chronic hepatitis B or C (35 studies), [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] NAFLD or NASH (15 studies), [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , …”